Oryzon raises €12M and secures €25M from COFIDES for its clinical programs -

Funding and Innovation

The biopharmaceutical company Oryzon Genomics has successfully completed a €12 million capital increase. Simultaneously, it has signed an agreement with COFIDES committing a future investment of €25 million to accelerate its clinical programs in oncology and mental health.

In a key move to consolidate its position in global markets, the leading company in epigenetics Oryzon Genomics has captured 12 millones de euros of gross financing through the issuance of 4.444.445 new ordinary shares. The corporate transaction has set a subscription price of €2,70 per share, representing a strategic discount of 14,15% compared to the volume-weighted average price (VWAP) of the last five trading sessions, and 12,68% compared to the previous day's market close.

This capital injection, structured without the issuance of warrants, has had the support of key financial players in the field of international investments. Singular Bank has acted as an underwriter in the Spanish market, while All-Invest It has led the placement in the European Union and the United Kingdom, demonstrating the interest of foreign capital in the biotechnology company. Meanwhile, Banco Sabadell has acted as an agent and technical pre-financier, with legal advice from Gómez-Acebo & Pombo.

The company's roadmap states that these funds will be used to strengthen its balance sheet for future growth. international alliances and advance the clinical development of the molecule iadademstat, key in the treatment of acute myeloid leukemia, in addition to covering operational and administrative needs.

Regarding this financial milestone, the Dr. Carlos BuesaThe company's CEO has highlighted the importance of the current moment: “This funding comes at a particularly important time for Oryzon and strengthens our ability to execute our clinical strategy more robustly. The progress of our acute myeloid leukemia program is generating increasing attention in the international oncology ecosystem, both among specialists and pharmaceutical companies and specialized investors. With this support, we gain financial flexibility to accelerate our priority programs and continue exploring strategic opportunities that can maximize the value of our platform.”.

A strategic alliance backed by European funds

Along with this expansion, the company has signed a subscription agreement with the Social Impact Fund, an instrument managed by COFIDES and linked to the Ministry of Inclusion, Social Security and Migration through the European mechanism NextGenerationEUThis agreement makes the public entity an anchor investor, committing up to 25 millones de euros for future capital increases that the biopharmaceutical company decides to carry out within a period of six months, extendable by mutual agreement.

This important flow of corporate financing It is conditional upon meeting business and social impact objectives. Specifically, oryzon It commits to allocating all of these resources to R&D for the central nervous system, oncology, and hematology. Furthermore, a key clause in the agreement requires that at least 40% of the funds Invest in addressing unmet medical needs in mental health, prioritizing the treatment of borderline personality disorder.

El Dr. Buesa He greatly valued this institutional collaboration, highlighting its impact on the company's positioning vis-à-vis foreign funds: “The alliance with the COFIDES Social Impact Fund represents much more than a financial commitment: it is a recognition of the transformative potential of our mental health programs. That an institution of this stature has validated the project from a scientific, business, and social impact perspective reinforces our conviction that Oryzon can play a significant role in an area where medical needs remain enormous. This agreement provides us with credibility, visibility, and the capacity to move forward with greater momentum in the development of innovative therapies for psychiatric disorders. Having an internationally renowned institutional partner strengthens the project's credibility and facilitates dialogue with specialized international funds.”.

Key points and frequently asked questions about Oryzon and COFIDES financing

From an internationalization perspective, what does this double operation imply for a Spanish biopharmaceutical company?

For a company like OryzonThis dual operation validates its strategy in the global market. The capital increase demonstrates the confidence of private investors, while the commitment of COFIDESA public-private institutional investor brings a seal of credibility and solvency that facilitates dialogue with international funds and pharmaceutical companies, opening doors to future strategic alliances and collaborations worldwide.

What is the strategic impact of the agreement with the COFIDES Social Impact Fund?

The agreement is not only financial, but also strategic. It aligns Oryzon with the impact investment guidelines and the objectives of the funds NextGenerationEUfocused on projects with a clear social benefit. This positioning in the field of mental health, an area of high medical need, strengthens its ESG (Environmental, Social and Governance) profile and increases its attractiveness to a broader spectrum of international investors specializing in sustainability.

What are the implications of this funding for Oryzon's clinical programs?

The €12 million capital injection and the future commitment of €25 million provide the necessary financial "fuel" to accelerate its most promising programs without interruption. Specifically, it allows for faster progress in the trials of iadademstat against acute myeloid leukemia and, crucially, decisively boosts the mental health portfolio. This reduces financial risk and gives the company greater flexibility to negotiate from a position of strength.